PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis

Diagnostic Pathology

Volumn 10, Issue 1, 2015, Pages

  Leite, Katia R M ^a,b   Reis, Sabrina T ^a   Junior, José Pontes ^a   Zerati, Marcelo ^a   Gomes, Daniel de Oliveira ^a   Camara Lopes, Luiz H ^b   Srougi, Miguel ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Genoa Biotecnologia SA Department of Molecular Biology   (Brazil)

Author keywords

Immunohistochemistry; Immunotherapy; PD L1; Prognosis; Renal cell cancer

Indexed keywords

CD274 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER;

AGED; CANCER GRADING; CARCINOMA, RENAL CELL; CHEMISTRY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; NEPHRECTOMY; PATHOLOGY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE;

AGED; ANTIGENS, CD274; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEPHRECTOMY; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 84945186513     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/s13000-015-0414-x     Document Type: Article

References (23)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144:646-74.
2. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-pd-1 antibody in cancer. N Engl J Med. 2012;366:2443-54.
3. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-pd-l1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-65.
4. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51-81.
5. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-64.
6. Zou W, Chen L. Inhibitory b7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467-77.
7. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, et al. Pd-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13:1757-61.
8. Gunturi A, McDermott DF. Potential of new therapies like anti-pd1 in kidney cancer. Curr Treat Options in Oncol. 2014;15:137-46.
9. Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, et al. Members of the ISUP Renal Tumor Panel. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37:1490-504.
10. Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, Gasser T, et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol. 1999;154:981-6.
11. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80:1943-9.
12. Dall'Oglio MF, Ribeiro-Filho LA, Antunes AA, Crippa A, Nesrallah L, Gonçalves PD, et al. Microvascular tumor invasion, tumor size and fuhrman grade: a pathological triad for prognostic evaluation of renal cell carcinoma. J Urol. 2007;178:425-8. discussion 428.
13. Dong H, Zhu G, Tamada K, Chen L. B7-h1, a third member of the b7 family, co-stimulates t-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365-9.
14. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793-800.
15. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of pd-l1 on tumor cells in the escape from host immune system and tumor immunotherapy by pd-l1 blockade. Proc Natl Acad Sci U S A. 2002;99:12293-7.
16. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66:3381-5.
17. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al, et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004;101:17174-9.
18. Choueiri TK, Figueroa DJ, Fay AP, Signoretti S, Liu Y, Gagnon R, et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Can Res. 2015;21:1071-7.
19. Jilaveanu LB, Shuch B, Zito CR, Parisi F, Barr M, Kluger Y, et al. PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases. J Cancer. 2014;5:166-72.
20. Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol. 2014;25:2178-84.
21. Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015;6:5449-64.
22. Qing Y, Li Q, Ren T, Xia W, Peng Y, Liu GL, et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther. 2015;9:901-9.
23. Wang A, Wang HY, Liu Y, Zhao MC, Zhang HJ, Lu ZY, et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. Eur J Surg Oncol. 2015;41:450-6.